{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:37:06Z","timestamp":1778888226057,"version":"3.51.4"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","award":["HRA_POR\/2010\/19"],"award-info":[{"award-number":["HRA_POR\/2010\/19"]}],"id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","award":["HRA_POR\/2013\/237"],"award-info":[{"award-number":["HRA_POR\/2013\/237"]}],"id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2019.00089","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T05:11:51Z","timestamp":1551157911000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?"],"prefix":"10.3389","volume":"10","author":[{"given":"Anne-Marie","family":"Baird","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Easty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Jarzabek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liam","family":"Shiels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Soltermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Klebe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Raeppel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"MacDonagh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengguang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Griggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela B.","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Stanfill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Nonaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandra M.","family":"Goparaju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Murer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean A.","family":"Fennell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dearbhaile M.","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin P.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Mutti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glen","family":"Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Finn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinead","family":"Cuffe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harvey I.","family":"Pass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Opitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette T.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth J.","family":"O'Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven G.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,2,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1136\/oem.17.4.260","article-title":"Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province","volume":"17","author":"Wagner","year":"1960","journal-title":"Br J Ind Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(95)90462-X","article-title":"Continuing increase in mesothelioma mortality in Britain","volume":"345","author":"Peto","year":"1995","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/s0140-6736(05)67025-0","article-title":"Malignant mesothelioma","volume":"366","author":"Robinson","year":"2005","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/ajim.20209","article-title":"The global burden of disease due to occupational carcinogens","volume":"48","author":"Driscoll","year":"2005","journal-title":"Am J Ind Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/sj.bjc.6605781","article-title":"Projection of mesothelioma mortality in Britain using Bayesian methods","volume":"103","author":"Tan","year":"2010","journal-title":"Br J Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1289\/ehp.1002845","article-title":"Global magnitude of reported and unreported mesothelioma","volume":"119","author":"Park","year":"2011","journal-title":"Environ Health Perspect."},{"key":"B7","doi-asserted-by":"publisher","first-page":"v31-9","DOI":"10.1093\/annonc\/mdv199","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger","volume":"26","author":"Baas","year":"2015","journal-title":"Ann Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/jco.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nrc3277","article-title":"Spatial regulation of receptor tyrosine kinases in development and cancer","volume":"12","author":"Casaletto","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1158\/0008-5472.can-04-4567","article-title":"Functional analysis of c-Met\/hepatocyte growth factor pathway in malignant pleural mesothelioma","volume":"66","author":"Jagadeeswaran","year":"2006","journal-title":"Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/carcin\/bgp097","article-title":"Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells","volume":"30","author":"Kawaguchi","year":"2009","journal-title":"Carcinogenesis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1097\/JTO.0b013e318215a07d","article-title":"Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy","volume":"6","author":"Brevet","year":"2011","journal-title":"J Thorac Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/onc.2010.555","article-title":"AXL regulates mesothelioma proliferation and invasiveness","volume":"30","author":"Ou","year":"2011","journal-title":"Oncogene"},{"key":"B14","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/bjc.2013.9","article-title":"The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma","volume":"108","author":"Pinato","year":"2013","journal-title":"Br J Cancer"},{"key":"B15","first-page":"2627","article-title":"The proto-oncogene RON is involved in development of epithelial, bone and neuro-endocrine tissues","volume":"11","author":"Gaudino","year":"1995","journal-title":"Oncogene"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1172\/jci6091","article-title":"The Ron\/STK receptor tyrosine kinase is essential for peri-implantation development in the mouse","volume":"103","author":"Muraoka","year":"1999","journal-title":"J Clin Invest."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3524","DOI":"10.1002\/j.1460-2075.1994.tb06659.x","article-title":"RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP","volume":"13","author":"Gaudino","year":"1994","journal-title":"EMBO J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nrc3545","article-title":"MSP-RON signalling in cancer: pathogenesis and therapeutic potential","volume":"13","author":"Yao","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1158\/0008-5472.can-04-0600","article-title":"Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression","volume":"64","author":"Bardella","year":"2004","journal-title":"Cancer Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1177\/1947601911421924","article-title":"Short-form Ron promotes spontaneous breast cancer metastasis through interaction with phosphoinositide 3-kinase","volume":"2","author":"Liu","year":"2011","journal-title":"Genes Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.celrep.2013.12.010","article-title":"The RON receptor tyrosine kinase promotes metastasis by triggering MBD4-dependent DNA methylation reprogramming","volume":"6","author":"Cunha","year":"2014","journal-title":"Cell Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S0014-4827(03)00280-5","article-title":"Cross-talk between the receptor tyrosine kinases Ron and epidermal growth factor receptor","volume":"289","author":"Peace","year":"2003","journal-title":"Exp Cell Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1158\/0008-5472.can-10-2100","article-title":"Ron kinase transphosphorylation sustains MET oncogene addiction","volume":"71","author":"Benvenuti","year":"2011","journal-title":"Cancer Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"18661","DOI":"10.1073\/pnas.1412228112","article-title":"Genetic modifiers of EGFR dependence in non-small cell lung cancer","volume":"111","author":"Sharifnia","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B25","doi-asserted-by":"publisher","first-page":"a009076","DOI":"10.1101\/cshperspect.a009076","article-title":"Biology of the TAM receptors","volume":"5","author":"Lemke","year":"2013","journal-title":"Cold Spring Harb Perspect Biol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1038\/bjc.2014.220","article-title":"Multipoint targeting of the PI3K\/mTOR pathway in mesothelioma","volume":"110","author":"Zhou","year":"2014","journal-title":"Br J Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.18632\/oncotarget.3420","article-title":"Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets","volume":"6","author":"Chang","year":"2015","journal-title":"Oncotarget"},{"key":"B28","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1158\/0008-5472.can-12-3583","article-title":"Dramatic antitumor effects of the dual MET\/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer","volume":"74","author":"Kawada","year":"2014","journal-title":"Cancer Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"6105","DOI":"10.1158\/0008-5472.can-05-0207","article-title":"A five-amino-acid peptide blocks Met- and Ron-dependent cell migration","volume":"65","author":"Matzke","year":"2005","journal-title":"Cancer Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1016\/j.bmcl.2010.03.073","article-title":"Identification of a novel series of potent RON receptor tyrosine kinase inhibitors","volume":"20","author":"Raeppel","year":"2010","journal-title":"Bioorg Med Chem Lett."},{"key":"B31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1476-4598-10-82","article-title":"The monoclonal antibody Zt\/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells","volume":"10","author":"Yao","year":"2011","journal-title":"Mol Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e69992","DOI":"10.1371\/journal.pone.0069992","article-title":"Ron knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi)","volume":"8","author":"Zou","year":"2013","journal-title":"PLoS ONE"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1021\/jm801586s","article-title":"Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily","volume":"52","author":"Schroeder","year":"2009","journal-title":"J Med Chem."},{"key":"B34","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s10637-012-9912-9","article-title":"LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models","volume":"31","author":"Yan","year":"2013","journal-title":"Invest New Drugs"},{"key":"B35","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.molcel.2005.10.026","article-title":"Cell motility is controlled by SF2\/ASF through alternative splicing of the Ron protooncogene","volume":"20","author":"Ghigna","year":"2005","journal-title":"Mol Cell"},{"key":"B36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4161\/cbt.12.1.15747","article-title":"RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma","volume":"12","author":"Catenacci","year":"2011","journal-title":"Cancer Biol Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.prp.2011.05.006","article-title":"Tyrosine kinase receptor RON and its ligand MSP in Merkel cell carcinoma","volume":"207","author":"Nagahama","year":"2011","journal-title":"Pathol Res Pract."},{"key":"B38","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1593\/neo.07112","article-title":"Oncomine 3","volume":"9","author":"Rhodes","year":"2007","journal-title":"Neoplasia"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/s0002-9440(10)62492-3","article-title":"Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling","volume":"166","author":"Gordon","year":"2005","journal-title":"Am J Pathol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.cd-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"B41","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/JTO.0b013e3182417da5","article-title":"Plasma cell membrane localization of c-MET predicts longer survival in patients with malignant mesothelioma: a series of 157 cases from the MESOPATH Group","volume":"7","author":"Levallet","year":"2012","journal-title":"J Thorac Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.ejcts.2009.08.027","article-title":"Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma","volume":"37","author":"Schramm","year":"2010","journal-title":"Eur J Cardiothorac Surg."},{"key":"B43","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/PAT.0b013e328342016c","article-title":"Validation of tissue microarray technology in malignant pleural mesothelioma","volume":"43","author":"Kao","year":"2011","journal-title":"Pathology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1186\/1471-2407-14-970","article-title":"PROGgeneV2: enhancements on the existing database","volume":"14","author":"Goswami","year":"2014","journal-title":"BMC Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/emmm.201100176","article-title":"Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils","volume":"3","author":"Torti","year":"2011","journal-title":"EMBO Mol Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"280","DOI":"10.15252\/embr.201439949","article-title":"Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure","volume":"16","author":"Pagliarini","year":"2015","journal-title":"EMBO Rep."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1093\/carcin\/bgr086","article-title":"IGF1-R signals through the RON receptor to mediate pancreatic cancer cell migration","volume":"32","author":"Jaquish","year":"2011","journal-title":"Carcinogenesis"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1038\/srep02560","article-title":"IGF-1R\/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations","volume":"3","author":"Vazquez-Martin","year":"2013","journal-title":"Sci Rep."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1002\/ijc.28737","article-title":"The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor","volume":"135","author":"Suda","year":"2014","journal-title":"Int J Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.lungcan.2006.08.012","article-title":"EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma","volume":"54","author":"Edwards","year":"2006","journal-title":"Lung Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3727\/096504010X12828372551713","article-title":"RON and cisplatin resistance in ovarian cancer cell lines","volume":"19","author":"Prislei","year":"2010","journal-title":"Oncol Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1038\/sj.onc.1203620","article-title":"Cross-talk between the proto-oncogenes Met and Ron","volume":"19","author":"Follenzi","year":"2000","journal-title":"Oncogene"},{"key":"B53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12943-018-0796-y","article-title":"Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1093\/carcin\/bgg089","article-title":"Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase","volume":"24","author":"Wang","year":"2003","journal-title":"Carcinogenesis"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e1167","DOI":"10.1038\/cddis.2014.136","article-title":"Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation","volume":"5","author":"Cioce","year":"2014","journal-title":"Cell Death Dis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1517\/13543784.2015.971154","article-title":"Discontinued in 2013: oncology drugs","volume":"24","author":"Williams","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"B57","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1016\/j.bmcl.2015.07.080","article-title":"Design, synthesis and RON receptor tyrosine kinase inhibitory activity of new head groups analogs of LCRF-0004","volume":"25","author":"Raeppel","year":"2015","journal-title":"Bioorg Med Chem Lett."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1016\/j.bmcl.2015.04.056","article-title":"Design and synthesis of close analogs of LCRF-0004, a potent and selective RON receptor tyrosine kinase inhibitor","volume":"25","author":"Raeppel","year":"2015","journal-title":"Bioorg Med Chem Lett."},{"key":"B59","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1016\/j.bmcl.2015.06.034","article-title":"Design and synthesis of constrained analogs of LCRF-0004 as potent RON tyrosine kinase inhibitors","volume":"25","author":"Raeppel","year":"2015","journal-title":"Bioorg Med Chem Lett."},{"key":"B60","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/ijms19113560","article-title":"Special issue on mechanisms of mesothelioma heterogeneity: highlights and open questions","volume":"19","author":"Felley-Bosco","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1038\/oncsis.2013.36","article-title":"Knockdown of RON receptor kinase delays but does not prevent tumor progression while enhancing HGF\/MET signaling in pancreatic cancer cell lines","volume":"2","author":"Zhao","year":"2013","journal-title":"Oncogenesis"},{"key":"B62","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1158\/1078-0432.ccr-13-1559","article-title":"Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer","volume":"20","author":"Yoshida","year":"2014","journal-title":"Clin Cancer Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1074\/mcp.M117.067439","article-title":"Quantitative tyrosine phosphoproteomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor-treated lung adenocarcinoma cells reveals potential novel biomarkers of therapeutic response","volume":"16","author":"Zhang","year":"2017","journal-title":"Mol Cell Proteomics"},{"key":"B64","doi-asserted-by":"publisher","first-page":"9876","DOI":"10.18632\/oncotarget.7130","article-title":"Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo","volume":"7","author":"Onken","year":"2016","journal-title":"Oncotarget"},{"key":"B65","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/1098-2264(2000)9999:9999<::AID-GCC1015>3.0.CO;2-N","article-title":"Gene structure of the human receptor tyrosine kinase RON and mutation analysis in lung cancer samples","volume":"29","author":"Angeloni","year":"2000","journal-title":"Genes Chromosomes Cancer"},{"key":"B66","first-page":"357","article-title":"Cell Viability Assays","author":"Riss","year":"2004"},{"key":"B67","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10585-011-9447-z","article-title":"Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation","volume":"29","author":"Dai","year":"2012","journal-title":"Clin Exp Metastasis"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2019.00089\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T05:11:54Z","timestamp":1551157914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2019.00089\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,26]]},"references-count":67,"alternative-id":["10.3389\/fendo.2019.00089"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2019.00089","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,26]]},"article-number":"89"}}